← All trials
NCT05450965
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2022
- Primary completion
- Aug 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Jul 11, 2022
- Last posted
- Aug 2, 2022
- Enrollment
- 37
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PittsburghLead sponsor
- National Institutes of Health (NIH)Collaborator
- University of PittsburghOverall official - principal investigator
- University of PittsburghSponsor investigator
- Cardiff OncologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.